ALDEYRA THERAPEUTICS INC (ALDX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ALDX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALDX | Director | 73 | ["Senior Vice President, Corporate Development of Genzyme Corporation","Led Genzyme Corporation’s Corporate Development team from 1989 to 2011","Involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances","Served in science and corporate development capacities at Integrated Genetics","Currently on the board of directors of Novavax, Inc.","Chairs the Board of Directors of MaxCyte, Inc.","Member of the University of Michigan Innovation Partnerships National Advisory Board","Advisor to Red Sky Partners LLC"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NVAX | Former Senior Vice President, Corporate Development; Independent Director; Member | 73 | ["Industry Experience","Executive Leadership","Accounting, Financial or Investment Experience","Public Company Board","Former Senior Vice President, Corporate Development at Genzyme Corporation","Led Genzyme Corporation’s Corporate Development team","Involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances","Served in science and corporate development capacities at Integrated Genetics","Postdoctoral fellow at the California Institute of Technology","Ph.D. in Biochemistry from University of California, Berkeley","Bachelor of Science in Chemistry from University of Michigan"] | ["Audit","Research & Development","Research and Development Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Douglas has served on our Board of Directors since September 2016. Dr. Douglas was formerly Senior Vice President, Corporate Development of Genzyme Corporation. From 1989 to 2011, he led Genzyme Corporation s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until the merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the board of directors of Novavax, Inc., a publicly-traded commercial vaccine company; chairs the Board of Directors of MaxCyte, Inc., a publicly traded instrument company; and is on the University of Michigan Innovation Partnerships National Advisory Board. Dr. Douglas is also an advisor to Red Sky Partners LLC. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood s laboratory at the California Institute of Technology. Dr. Douglas s extensive knowledge of our business; experience as a board member of publicly-traded biotechnology companies; substantial scientific background; and expertise in developing, financing and providing strong executive leadership within the pharmaceutical industry contributed to our conclusion that he should serve as a director of our company.